Although many 99mTc-labeled glutamate-urea-based PSMA-targeted inhibitors have been evaluated as prostate cancer imaging agents, direct comparison is difficult due to the different experimental conditions. This evidence concerns the gene FOLH1 and prostate carcinoma.